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The TGFβ pathway has essential roles in embryonic development, 
organ homeostasis, tissue repair and disease1,2. These diverse effects 
are mediated through the intracellular effectors SMAD2 and SMAD3 
(hereafter SMAD2/3), whose canonical function is to control the 
activity of target genes by interacting with transcriptional regulators3. 
Therefore, a complete description of the factors that interact with 
SMAD2/3 in a given cell type would have broad implications for many 
areas of cell biology. Here we describe the interactome of SMAD2/3 
in human pluripotent stem cells. This analysis reveals that SMAD2/3 
is involved in multiple molecular processes in addition to its role 
in transcription. In particular, we identify a functional interaction 
with the METTL3–METTL14–WTAP complex, which mediates the 
conversion of adenosine to N6-methyladenosine (m6A) on RNA4. We 
show that SMAD2/3 promotes binding of the m6A methyltransferase 
complex to a subset of transcripts involved in early cell fate decisions. 
This mechanism destabilizes specific SMAD2/3 transcriptional 
targets, including the pluripotency factor gene NANOG, priming 
them for rapid downregulation upon differentiation to enable 
timely exit from pluripotency. Collectively, these findings reveal 
the mechanism by which extracellular signalling can induce rapid 
cellular responses through regulation of the epitranscriptome. These 
aspects of TGFβ signalling could have far-reaching implications in 
many other cell types and in diseases such as cancer5.
Activin and NODAL, two members of the TGFβ superfamily, 
play essential roles in cell fate decision in human pluripotent stem 
cells (hPSCs)6–8. Activin–NODAL signalling is necessary to main-
tain pluripotency, and inhibition of this pathway drives differen-
tiation towards the neuroectoderm lineage6,9,10. Activin–NODAL 
 signalling also cooperates with BMP and WNT pathways to drive 
mesendoderm  specification11–14. We therefore used the differentia-
tion of hPSCs into definitive endoderm as a model system to inves-
tigate the SMAD2/3 interactome during a dynamic cellular process. 
To allow a comprehensive and unbiased examination of the proteins 
that  interact with SMAD2/3, we developed an optimized SMAD2/3 
co- immunoprecipitation protocol that is compatible with mass- 
spectrometry  analyses (Extended Data Fig. 1a, b and Supplementary 
Discussion). By examining human embryonic stem cells (hESCs) and 
hESCs that have been induced to differentiate to endoderm (Fig. 1a), we 
identified 89 interacting partners of SMAD2/3 (Fig. 1b, Extended Data 
Fig. 1c, d and Supplementary Table 1). Eleven of these proteins inter-
acted with SMAD2/3 either in hESCs or the differentiating cells but not 
in both (Extended Data Fig. 1e), suggesting that the SMAD2/3 interac-
tome is largely conserved across these two cell types (Supplementary 
Discussion). Notably, this list includes known SMAD2/3 transcrip-
tional and epigenetic cofactors (including FOXH1, SMAD4, SNON, 
SKI, EP300, SETDB1 and CREBBP3). We also performed functional 
experiments on FOXH1, EP300, CREBBP and SETDB1, which 
 uncovered essential functions of these SMAD2/3 transcriptional and 
epigenetic cofactors in hPSC fate decisions (Extended Data Figs 2, 3 
and Supplementary Discussion).
These proteomic experiments also show that SMAD2/3 interacts 
with complexes involved in functions that have, to our knowledge, 
not previously been associated with TGFβ signalling (Fig. 1b and 
Extended Data Fig. 1f), such as ERCC1–XPF and DAPK3–PAWR. 
which are involved in DNA repair and apoptosis, respectively. We also 
identified several factors involved in mRNA processing, modification 
and degradation (Fig. 1b), such as the METTL3–METTL14–WTAP 
complex (involved in deposition of N6-methyladenosine (m6A)), the 
PABP-dependent poly(A) nuclease complex (PAN, involved in mRNA 
decay), the cleavage factor complex CFIm (involved in pre-mRNA 
3′ end processing) and the NONO–SFPQ–PSPC1 factors (involved in 
RNA splicing and nuclear retention of defective RNAs). Overall, these 
results suggest that SMAD2/3 could be involved in a large number of 
biological processes in hPSCs, including not only transcriptional and 
epigenetic regulation, but also non-canonical functions of SMAD2/3.
To further investigate these functions, we examined the function of 
activin–NODAL signalling in m6A deposition. m6A is the most common 
RNA modification, and it regulates multiple aspects of mRNA biology 
including decay and translation4,15–19. However, it is not known whether 
this is a dynamic event that can be modulated by extracellular cues. 
Furthermore, whereas m6A is known to regulate haematopoietic stem 
cells20,21 and the transition between the naive and primed pluripotency 
states22,23, its function in hPSCs and during germ layer specification is 
unknown. We first validated the interaction of SMAD2/3 with METTL3–
METTL14–WTAP by co-immunoprecipitation followed by western 
blotting with both hESCs and human induced pluripotent stem cells 
(hiPSCs; Fig. 2a and Extended Data Fig. 4a, b). Inhibition of SMAD2/3 
phosphorylation blocked this interaction (Fig. 2b and Extended Data 
Fig. 4c). Proximity ligation assays (PLA) also demonstrated that the inter-
action occurs in the nucleus (Fig. 2c, d). These observations suggest that 
SMAD2/3 and the m6A methyltransferase complex interact and that this 
interaction depends on activin–NODAL signalling.
To investigate the functional relevance of this interaction, we 
assessed the transcriptome-wide effects of inhibition of activin–
NODAL signalling on the deposition of m6A by performing nuclear- 
enriched m6A-methylated-RNA immunoprecipitation followed 
by deep sequencing (NeMeRIP–seq; Extended Data Fig. 5a–d, and 
Supplementary Discussion). Consistent with previous reports17,19,24, 
deposition of m6A onto exons was enriched around stop codons and 
transcription start sites, and occurred at a motif corresponding to the 
m6A-consensus sequence (Extended Data Fig. 5e–g). Assessment of 
differential m6A deposition revealed that inhibition of activin–NODAL 
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signalling predominantly resulted in decreased m6A levels in selected 
transcripts (Supplementary Table 2; mean absolute log2 fold-change of 
0.56 and 0.35 for m6A decrease and increase, respectively). Decreases 
in m6A deposition were mostly observed on peaks located near stop 
codons (Extended Data Fig. 5h), where m6A deposition has been 
reported to decrease the stability of mRNAs16,24,25. Transcripts with 
reduced m6A levels after inhibition of activin–NODAL signalling 
largely and significantly overlapped with genes bound by SMAD2/3 
(P < 2.88 × 10−18; Extended Data Fig. 5i), including well-known tran-
scriptional targets such as NANOG, NODAL, LEFTY1 and SMAD7 
(Fig. 2e and Extended Data Fig. 5j). Accordingly, activin–NODAL-
sensitive m6A deposition was largely associated with transcripts that 
rapidly decreased in abundance during the exit from pluripotency 
triggered by inhibition of activin–NODAL signalling (Extended Data 
Fig. 6a). Transcripts that behaved in this fashion were enriched in 
pluripotency regulators and factors involved in the activin–NODAL 
signalling pathway (Supplementary Table 3). On the other hand, the 
expression of a large number of developmental regulators associated 
with activin–NODAL-sensitive m6A deposition remained unchanged 
following inhibition of activin–NODAL signalling (Extended Data 
Fig. 6a–c and Supplementary Table 3). Considered together, these 
 findings show that activin–NODAL signalling can regulate m6A 
 deposition on a number of specific transcripts.
We then examined the molecular mechanisms that underlie the reg-
ulation of m6A deposition by activin–NODAL signalling. RNA immu-
noprecipitation experiments on nuclear RNAs showed that inhibition 
of activin–NODAL signalling impaired binding of WTAP to several 
m6A-labelled transcripts including NANOG and LEFTY1 (Fig. 2f and 
Extended Data Fig. 4d, e), whereas SMAD2/3 itself interacted with 
these transcripts in the presence of activin–NODAL signalling (Fig. 
2g and Extended Data Fig. 4e). Thus, SMAD2/3 appears to promote 
the recruitment of the m6A methyltransferase complex to nuclear 
RNAs. Notably, recent reports have established that m6A deposition 
occurs co-transcriptionally and involves nascent pre-RNAs16,20,26. 
Considering the broad overlap between SMAD2/3 transcriptional tar-
gets and transcripts showing activin–NODAL-sensitive m6A deposition 
(Extended Data Fig. 5i), we hypothesized that SMAD2/3 could facilitate 
co- transcriptional recruitment of the m6A methyltransferase com-
plex onto nascent transcripts. Consistent with this notion, inhibition 
of activin–NODAL signalling mainly resulted in downregulation 
of m6A, not only on exons, but also on pre-mRNA-specific features 
such as introns and exon–intron junctions (Extended Data Fig. 6d–i 
and Supplementary Table 2). Moreover, we observed a correlation in 
activin–NODAL sensitivity across m6A peaks within the same tran-
script (Extended Data Fig. 6j), suggesting that SMAD2/3 regulates m6A 
deposition at the level of the genomic locus rather than on a specific 
mRNA peak. Nevertheless, we did not detect stable and direct binding 
of the m6A methyltransferase complex to DNA (Extended Data Fig. 4f). 
Thus, co-transcriptional recruitment might rely on indirect and 
dynamic interactions with chromatin. Considering all these results, 
we propose a model in which activin–NODAL signalling promotes 
co- transcriptional m6A deposition by facilitating the recruitment of 
the m6A methyl transferase complex onto nascent mRNAs (Fig. 2h).
To understand the functional relevance of this regulation in the con-
text of hPSC cell-fate decisions, we performed inducible knockdown of 
the subunits of the m6A methyltransferase complex27 (Extended Data 
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Figure 1 | Identification of the SMAD2/3 
interactome. a, Experimental approach. 
IP, immunoprecipitation. RP-HPLC, 
reversed-phase high-performance liquid 
chromatography; MS/MS, tandem mass 
spectrometry. b, Interaction network of all 
known protein–protein interactions between 
selected SMAD2/3 partners identified in 
pluripotent and endoderm cells (n = 3  
co-immunoprecipitations; one-tailed t-test, 
permutation-based false discovery rate 
(FDR) < 0.05). Nodes describe: (1) the lineage 
in which the proteins were significantly 
enriched (shape); (2) the significance of 
the enrichment (size is proportional to the 
maximum − log P value); and (3) the function 
of the factors (colour). Complexes of interest 
are marked.
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Fig. 7a, b). As expected, reducing expression of WTAP, METTL14 
or METTL3 decreased m6A deposition (Extended Data Fig. 7c, d); 
 however, prolonged knockdown did not affect pluripotency (Extended 
Data Fig. 7e, f). We also found that expression of m6A methyltrans-
ferase complex subunits was necessary for neuroectoderm differ-
entiation induced by the inhibition of activin–NODAL signalling 
without being necessary for activin-driven endoderm specification 
(Fig. 3a and Extended Data Fig. 8a–c). Notably, Activin–NODAL is 
known to block neuroectoderm induction by promoting NANOG 
expression28, whereas NANOG is required for the early stages of endo-
derm  specification13. Accordingly, we found that NANOG transcript 
and protein were upregulated, and the stability of NANOG mRNA 
increased when m6A methyltransferase activity was impaired (Fig. 3b 
and Extended Data Fig. 9a–c). These results show that m6A deposition 
decreases the stability of NANOG mRNA, facilitating its downregulation 
upon loss of activin–NODAL signalling, and thereby facilitating exit 
from pluripotency and neuroectoderm specification (Extended Data 
Fig. 9d). Additional transcriptomic analyses showed that WTAP knock-
down resulted in global upregulation of genes that were transcription-
ally activated by SMAD2/3 in hESCs and impaired the upregulation 
of genes induced by inhibition of activin–NODAL signalling during 
neuroectoderm differentiation (Fig. 3b, Extended Data Fig. 10a–e, 
Supplementary Table 4 and Supplementary Discussion). Notably, the 
decrease in WTAP expression also led to upregulation of m6A-marked 
mRNAs (Extended Data Fig. 10f), confirming that WTAP-dependent 
m6A deposition destabilizes mRNAs16,24,25. Moreover, transcripts that 
are rapidly downregulated after inhibition of activin–NODAL signal-
ling were enriched in m6A-marked mRNAs (Extended Data Fig. 10f). 
Finally, simultaneous knockdown of METTL3, METTL14 and WTAP 
in hESCs resulted in an even stronger dysregulation of target transcripts 
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Figure 2 | Activin–NODAL signalling promotes m6A deposition on 
specific regulators of pluripotency and differentiation. a, b, Western blots 
of SMAD2/3 (S2/3), METTL3 (M3) or control (IgG) immunoprecipitations 
from nuclear extracts of hESCs (representative of three experiments). 
Input is 5% of the material used for immunoprecipitation. In b, 
immunoprecipitations were performed on hESCs maintained in the 
presence of activin or treated for 1 h with the activin–NODAL inhibitor 
SB431542 (SB). For gel Source Data, see Supplementary Fig. 1. c, Proximity 
ligation assays (PLA) for SMAD2/3 and WTAP in hESCs maintained in the 
presence of activin or SB431542 (representative of two experiments). Scale 
bars, 10µ m. DAPI, nuclei. d, PLA quantification; the known SMAD2/3 
cofactor NANOG was used as positive control10. Mean ± s.e.m., n = 4 
PLAs; two-way analysis of variance (ANOVA) with post hoc Holm–Sidak 
comparisons. e, Representative results of nuclear-enriched m6A-methylated 
RNA immunoprecipitation followed by deep sequencing (m6A NeMeRIP–
seq; n = 3 cultures, replicates combined for visualization). Signal represents 
read enrichment normalized per million mapped reads and library size. 
GENCODE gene annotations (red, coding exons; white, untranslated exons; 
all potential exons are shown and overlaid) and SMAD2/3-binding sites 
from chromatin immunoprecipitation followed by deep sequencing (ChIP–
seq) data30 are shown. f, g, RNA immunoprecipitation (RIP) experiments 
for WTAP, SMAD2/3 or IgG control in hESCs maintained in the presence of 
activin or treated with SB431542. RPLP0 and PBGD were used as negative 
controls as they do not contain m6A. In f, mean ± s.e.m., n = 3 cultures. Two-
way ANOVA with post hoc Holm-Sidak comparisons. In g, bars show mean, 
n = 2 cultures. h, Model of the mechanism by which SMAD2/3 promotes 
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Figure 3 | The m6A methyltransferase complex antagonizes activin–
NODAL signalling in hPSCs to promote timely exit from pluripotency.  
a, Immunofluorescence for the neural marker SOX1 following 
neuroectoderm differentiation of tetracycline (TET)-inducible knockdown 
(iKD) hESCs (representative of two experiments). Control, no tetracycline; 
scale bars, 100µ m. b, Quantitative PCR (qPCR) analyses in WTAP-iKD 
hESCs with inhibition of activin–NODAL signalling using SB431542 
treatments with indicated duration. Mean ± s.e.m., n = 3 cultures. Two-
way ANOVA with post hoc Holm-Sidak comparisons. c, Western blot 
validation of multiple inducible knockdown (MiKD) hESCs (iKD of WTAP, 
METTL3 and METTL14). Cells expressing three copies of the scrambled 
shRNA (SCR3× ) were used as negative control. d, qPCR analyses in 
undifferentiated MiKD hESCs, or following differentiation of MiKD hESCs 
to neuroectoderm. Mean ± s.e.m., n = 3 cultures. Two-tailed t-test.
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defective neuroectoderm differentiation (Fig. 3d and Extended Data 
Fig. 8e, f). Together, these results show that the interaction of SMAD2/3 
with METTL3–METTL14–WTAP can promote m6A deposition on a 
subset of transcripts, including a number of pluripotency regulators that 
are also transcriptionally activated by activin–NODAL signalling. The 
resulting negative feedback destabilizes these mRNAs and causes their 
rapid degradation following inhibition of activin–NODAL signalling. 
This mechanism allows timely exit from pluripotency and induction of 
neuroectoderm differentiation (Extended Data Fig. 9d).
In conclusion, this analysis of the SMAD2/3 interactome reveals 
interactions between TGFβ signalling and a wide variety of cellular 
processes. Our results suggest that SMAD2/3 could act as a hub, coor-
dinating several proteins known to have a role in mRNA  processing 
and modification, apoptosis, DNA repair and transcriptional 
regulation. This function is illustrated by our results that show activin–
NODAL-sensitive regulation of m6A. Activin–NODAL signalling con-
nects transcriptional and epitranscriptional regulation through the 
interaction between SMAD2/3 and the METTL3–METTL14–WTAP 
complex, and primes its transcriptional targets for rapid degradation 
upon withdrawal of signalling (Extended Data Fig. 9d). This avoids 
overlaps between the pluripotency and neuroectoderm transcriptional 
programs, thereby facilitating changes in cell identity. We anticipate 
that further studies will clarify the other non-canonical functions of 
SMAD2/3, and will dissect how they are related to epigenetic, transcrip-
tional and epitranscriptional regulation of gene expression.
Our findings also clarify and broaden our understanding of the 
function of m6A in cell-fate decisions. They establish that depletion of 
m6A in hPSCs does not lead to differentiation, contrary to predictions 
from studies in mouse-epiblast stem cells22. This could imply that there 
are important functional differences in epitranscriptional regulations 
between human and mouse pluripotent states. Moreover, widening the 
conclusions from previous reports23, we demonstrate that deposition of 
m6A is specifically necessary for neuroectoderm induction, but not for 
definitive endoderm differentiation. This can be explained by the fact that 
in contrast to its strong inhibitory effect on the neuroectoderm lineage28, 
expression of NANOG is necessary for the early stages of mesendoderm 
specification13,29. Finally, our results establish that m6A modification 
of RNA is a dynamic event that is directly modulated by extracellular 
cues such as TGFβ . Considering the many functions of TGFβ signalling, 
the regulation we describe here may have an essential function in many 
cellular contexts that require a rapid response or change in cell state, such 
as the inflammatory response or cellular proliferation.
Online Content Methods, along with any additional Extended Data display items and 
Source Data, are available in the online version of the paper; references unique to 
these sections appear only in the online paper.
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METHODS
hPSC culture and differentiation. Feeder- and serum-free culture of hESCs 
(H9/WA09 line; WiCell) and hiPSCs (A1ATR/R; ref. 31) have been previously 
described32. In brief, cells were plated on gelatin and MEF medium-coated plates, 
and cultured in chemically defined medium (CDM) containing bovine serum 
albumin (BSA). CDM was supplemented with 10 ng/ml activin-A and 12 ng/ml 
FGF2 (both from M. Hyvonen, Dept. of Biochemistry, University of Cambridge). 
Cells were passaged every 5–6 days with collagenase IV and plated as clumps of 
50–100 cells dispensed at a density of 100–150 clumps per cm2. Differentiation 
was initiated in adherent hESC cultures 48 h after passaging. Definitive endoderm 
specification was induced for three days (unless stated otherwise) by culturing 
cells in CDM (without insulin) with 20 ng/ml FGF2, 10 µ M LY294002 (PI3K 
 inhibitor; Promega), 100 ng/ml activin-A and 10 ng/ml BMP4 (R&D), as previously 
described33. Neuroectoderm was induced for three days (unless stated otherwise) 
in CDM-BSA with 12 ng/ml FGF2 and 10 µ M SB431542 (activin–NODAL–TGFβ 
signalling inhibitor; Tocris), as previously described34. These same culture con-
ditions were used for activin–NODAL signalling inhibition experiments. hPSCs 
were routinely monitored for absence of karyotypic abnormalities and mycoplasma 
infection. As hESCs were obtained from a commercial supplier, cell line identifica-
tion was not performed. hiPSCs were previously generated in house and genotyped 
by Sanger sequencing31.
Molecular cloning. Plasmids carrying inducible shRNAs were generated by 
 cloning annealed oligonucleotides into the pAAV-Puro_iKD or pAAV-Puro_siKD 
vectors as previously described27. All shRNA sequences were obtained from the 
RNAi Consortium TRC library35 (https://www.broadinstitute.org/rnai/public/). 
Of the shRNAs that had been validated, the most powerful ones were chosen 
(the sequences are reported in Supplementary Table 5). Generation of a vector 
 containing shRNAs against METTL3, METTL14 and WTAP (cloned in this order) 
was performed by Gibson assembly of PCR products containing individual shRNA 
cassettes, as previously described27. The resulting vector was named pAAV-Puro_
MsiKD-M3M14W. Generation of the matched control vector containing three 
copies of the scrambled shRNA sequence (pAAV-Puro_MsiKD-SCR3× ) has been 
described previously27.
A targeting vector for the AAVS1 locus carrying constitutively-expressed 
NANOG was generated starting from pAAV_TRE-eGFP36. First, the TRE-eGFP 
cassette was removed using PspXI and EcoRI, and substituted with the CAG 
 promoter (cut from pR26-CAG_eGFP27 using SpeI and BamHI) by ligating 
blunt-ended fragments. The resulting vector (pAAV-Puro_CAG) was then used 
to clone the full-length NANOG transcript, which includes its full 5′ and 3′ UTRs. 
The full-length NANOG transcript was constructed from three DNA fragments. 
The 5′ (bases 1–301) and 3′ (bases 1878–2105) ends were synthesized (IDT) with 
40 bp overlaps corresponding to pGem3Z vector linearized with SmaI. The middle 
fragment was amplified from cDNA of H9 hESCs obtained by retrotranscription 
with poly-T primer using primers 5′ -TTGTCCCCAAAGCTTGCCTTGCTTT-3′ 
and 5′ -CAAAAACGGTAAGAAATCAATTAA-3′ . The three fragments and the 
linearized vector were assembled using a Gibson reaction (NEB) and the sequence 
of the construct was confirmed by Sanger sequencing. The full length NANOG 
transcript was then subcloned into KpnI- and EcoRV-digested pAAV-Puro_CAG 
following KpnI and HincII digestion. The resulting vector was named pAAV-
Puro_CAG-NANOG.
Inducible gene knockdown. Clonal inducible knockdown hESCs for METTL3, 
METTL14, WTAP or matched controls expressing a scrambled (SCR) shRNA were 
generated by gene targeting of the AAVS1 locus with pAAV-Puro_siKD  plasmids, 
which was verified by genomic PCR, all as previously described27,36. This same 
approach was followed to generate multiple inducible knockdown hESCs for 
METTL3, METTL14 and WTAP (plasmid pAAV-Puro_MsiKD-M3M14W) or 
matched controls expressing three copies of the SCR shRNA (plasmid pAAV-Puro_
MsiKD-SCR3× ). Inducible knockdown hESCs for SMAD2, FOXH1, SETDB1, 
EP300, CREBBP, B2M and matched controls expressing a scrambled shRNA were 
generated using pAAV-Puro_iKD vectors27 in hESCs expressing a randomly inte-
grated wild-type tetracycline resistance gene. Two wells were transfected for each 
shRNA in order to generate independent biological replicates. Following selection 
with puromycin, the resulting targeted cells in each well were pooled and expanded 
for further analysis. Given that 20 to 50 clones were obtained for each well, we refer 
to these lines as ‘clonal pools’. Gene knockdown was induced by adding 1 µ g/ml 
tetracycline hydrochloride (Sigma-Aldrich) to the culture medium. Unless 
 indicated otherwise in the text or figure legends, inducible knockdown in 
 undifferentiated hESCs was induced for five days, while differentiation assays 
were performed in hESCs in which knockdown had been induced for ten days.
Generation of NANOG-overexpressing hESCs. NANOG-overexpressing H9 
hESCs were obtained by zinc-finger nuclease (ZFN)-facilitated gene targeting 
of the AAVS1 locus with pAAV-Puro_CAG-NANOG. This was performed by 
 lipofection of the targeting vector and zinc-finger plasmids followed by  puromycin 
 selection, clonal isolation and genotyping screening of targeted cells, all as 
 previously described27.
SMAD2/3 co-immunoprecipitation. Approximately 2 × 107 cells were used for 
each immunoprecipitation. Unless stated otherwise, all biochemical steps were 
performed on ice or at 4 °C, and ice-cold buffers were supplemented with complete 
protease inhibitors (Roche), PhosSTOP Phosphatase Inhibitor Cocktail (Roche), 
1 mg/ml leupeptin, 0.2 mM DTT, 0.2 mM PMSF and 10 mM sodium butyrate 
(all from Sigma-Aldrich). Cells were fed with fresh medium for 2 h before being 
washed with PBS, scraped in cell dissociation buffer (CDB, Gibco) and pelleted 
at 250 g for 10 min. The cell pellet was then washed once with 10 volumes of PBS, 
and once with 10 volumes of hypotonic lysis buffer (HLB; 10 mM HEPES pH 7.6, 
10 mM KCl, 2 mM MgCl2, 0.2 mM EDTA, 0.2 mM EGTA). The pellet was resus-
pended in 5 volumes of HLB and incubated for 5 min to induce cell swelling. The 
resulting cell suspension was homogenized using the ‘loose’ pestle of a Dounce 
homogenizer (Jencons Scientific) for 35–50 strokes until plasma membrane lysis 
was complete (as judged by microscopic inspection). The nuclei were pelleted 
at 800g for 5 min, washed once with ten volumes of HLB, and resuspended in 1.5 
volumes of high-salt nuclear lysis buffer (HSNLB; 20 mM HEPES pH 7.6, 420 mM 
NaCl, 2 mM MgCl2, 25% glycerol, 0.2 mM EDTA, 0.2 mM EGTA). High-salt nuclear 
extraction was performed by homogenizing the nuclei using the ‘tight’ pestle of a 
Dounce homogenizer for 70 strokes, followed by 45 min of incubation with rota-
tion. The resulting lysate was clarified for 30 min at 16,000g and transferred to a 
dialysis cassette using a 19-gauge syringe. Dialysis was performed for 4 h in 1 l of 
dialysis buffer (20 mM HEPES pH 7.6, 50 mM KCl, 100 mM NaCl, 2 mM MgCl2, 
10% glycerol, 0.2 mM EDTA, 0.2 mM EGTA) with gentle stirring, and the buffer 
was changed once after 2 h. After dialysis, the sample was clarified from minor pro-
tein precipitates for 10 min at 17,000g, and the protein concentration was assessed. 
Immunoprecipitations were performed by incubating 0.5 mg of protein with 5 µ g 
of goat polyclonal SMAD2/3 antibody (R&D systems, AF3797) or goat IgG nega-
tive control antibody (R&D systems, AB-108-C) for 3 h at 4 °C with  rotation. This 
was followed by incubation with 10 µ l of protein-G agarose for 1 h. Beads were 
washed three times with dialysis buffer and processed for western blot or mass 
spectrometry. This co-immunoprecipitation protocol is referred to as ‘co-IP2’ in the 
Supplementary Discussion and in Extended Data Fig. 1. The alternative SMAD2/3 
co-immunoprecipitation protocol (co-IP1) has been  previously described10.
Mass spectrometry. Label-free quantitative mass-spectrometric  analysis 
of proteins co-immunoprecipitated with SMAD2/3 or from control IgG 
co- immunoprecipitations was performed on three replicates for each condition. 
After immunoprecipitation, samples were prepared as previously described37 with 
minor modifications. Proteins were eluted by incubation with 50 µ l of 2 M urea 
and 10 mM DTT for 30 min at room temperature with agitation. Then, 55 mM 
chloroacetamide was added for 20 min to alkylate reduced disulfide bonds. Proteins 
were pre-digested on the beads with 0.4 µ g of mass-spectrometry-quality trypsin 
(Promega) for 1 h at room temperature with agitation. The suspension was 
cleared from the beads by centrifugation. The beads were then washed with 50 µ l 
of 2 M urea, and the combined supernatants were incubated overnight at room 
 temperature with agitation to complete digestion. 0.1% trifluoroacetic acid was 
then added to inactivate trypsin, and peptides were loaded on C18 StageTips38. Tips 
were prepared for binding by sequential equilibration for 2 min at 800g with 50 µ l 
methanol, 50 µ l Solvent B (0.5% acetic acid; 80% acetonitrile) and 50 µ l Solvent 
A (0.5% acetic acid). Subsequently, peptides were loaded and washed twice with 
Solvent A. Tips were stored in dry conditions until analysis. Peptides were eluted 
from the StageTips and separated by reversed-phase liquid chromatography on a 
2.5-h-long segmented gradient using EASY-nLC 1000 (ThermoFisher Scientific). 
Eluting peptides were ionized and injected directly into a Q Exactive mass spec-
trometer (ThermoFisher Scientific). The mass spectrometer was operated in 
TOP10 sequencing mode, meaning that one full mass-spectrometry scan was 
followed by higher energy collision induced dissociation (HCD) and subsequent 
detection of the fragmentation spectra of the 10 most abundant peptide ions 
(MS/MS). Collectively, ∼ 160,000 isotype patterns were generated resulting from 
∼ 6,000 mass-spectrometry runs. Consequently, ∼ 33,000 MS/MS spectra were 
measured.
Quantitative mass spectrometry based on dimethyl labelling of samples was 
performed as described for label-free quantitative mass spectrometry but with the 
following differences. Dimethyl labelling was performed as previously reported39,40. 
In brief, trypsin-digested protein samples were incubated with dimethyl labelling 
reagents (4 µ l of 0.6 M NaBH3CN together with 4 µ l of 4% CH2O or CD2O for light 
or heavy labelling, respectively) for 1 h at room temperature with agitation. The 
reaction was stopped by adding 16 µ l of 1% NH3. Samples were acidified with 0.1% 
trifluoroacetic acid, and finally loaded on StageTips. Each immunoprecipitation 
was performed twice, switching the labels.
Analysis of mass-spectrometry data. The raw label-free quantitative 
mass- spectrometry data were analysed using the MaxQuant software suite41. 
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Peptide spectra were compared against the human database (Uniprot) using 
the integrated Andromeda search engine, and peptides were identified with 
FDR < 0.01, determined by false matches against a reverse decoy database. Peptides 
were assembled into protein groups with an FDR < 0.01. Protein quantification was 
performed using the MaxQuant label-free quantification algorithm requiring at 
least two ratio counts, in order to obtain label-free quantification (LFQ)  intensities. 
Collectively, the MS/MS spectra were matched to ∼ 20,000 known peptides, leading 
to the identification of 3,635 proteins in at least one of the conditions analysed. 
Statistical  analysis of the data was performed using the Perseus software package 
(MaxQuant). First, common contaminants and reverse hits were removed, and 
only proteins identified by at least two peptides (one of those being unique to 
the respective protein group) were considered as high-confidence  identifications. 
Proteins were then filtered for those identified in all replicates of at least one 
 condition. LFQ intensities were converted to their log values, and missing  intensity 
values were imputed by representative noise values42. One-tailed t-tests were then 
performed to determine the specific interactors in each condition by  comparing 
the immunoprecipitations with the SMAD2/3 antibody to those with the IgG 
negative controls. Statistical significance was set with a permutation-based 
FDR < 0.05 (250 permutations). Fold-enrichment over IgG controls was calcu-
lated from LFQ intensities.
This same pipeline was used to analyse mass-spectrometry data based on 
dimethyl labelling, with the following two exceptions. First, an additional mass 
of 28.03 Da (light) or 32.06 Da (heavy) was specified as ‘labels’ at the N terminus 
and at lysines. Second, during statistical analysis of mass-spectrometry data, the 
outlier significance was calculated based on protein intensity (significance B41), and 
was required to be below 0.05 for both the forward and the reverse experiments.
Biological interpretation of mass-spectrometry data. The SMAD2/3 protein–
protein interaction network was generated using Cytoscape v.2.8.343. First, all the 
annotated interactions involving the SMAD2/3-binding proteins were inferred 
by interrogating protein–protein interaction databases through the PSIQUIC 
Universal Web Service Client. IMEx-complying interactions were retained and 
merged by union. Then, a subnetwork involving only the SMAD2/3 interactors was 
isolated. Finally, duplicate nodes and self-loops were removed to simplify visuali-
zation. Note that based on our results all the proteins shown would be connected 
to SMAD2/3, but such links were omitted to simplify visualization and highlight 
those interactions with SMAD2/3 that were already known. Proteins lacking any 
link and small complexes of less than three factors were not shown, in order to 
improve presentation clarity. Note that since the nodes representing SMAD2 and 
SMAD3 shared the same links, they were fused into a single node (SMAD2/3). 
Functional enrichment analysis was performed using Fisher’s exact test imple-
mented in Enrichr44, and only enriched terms with a Benjamini–Hochberg 
adjusted P value < 0.05 were considered. For Gene Ontology (GO) enrichment 
analysis, the 2015 GO annotation was used. For mouse phenotype enrichment 
analysis, level 3 of the Mouse Genomic Informatics (MGI) annotation was used. 
To compare protein abundance in different conditions, a cut-off of absolute LFQ 
intensity log2 fold-change larger than 2 was chosen, as label-free mass spectrometry 
is currently not sensitive enough to detect smaller changes with confidence37.
Proximity ligation assay. Proximity ligation assay (PLA) was performed using the 
Duolink In situ Red Starter Kit Goat/Rabbit (Sigma-Aldrich). Cells were cultured 
on glass coverslips and prepared by fixation in 4% paraformaldehyde (PFA) in 
PBS for 10 min at room temperature, followed by two gentle washes in PBS. All 
subsequent incubations were performed at room temperature unless otherwise 
stated. Samples were permeablilized in PBS containing 0.25% Triton X-100 for 
20 min, blocked in PBS with 0.5% BSA for 30 min, and incubated with the two 
primary antibodies of interest (diluted in PBS with 0.5% BSA; see Supplementary 
Table 6) for 1 h at 37 °C in a humid chamber. The Duolink In situ PLA probes 
(anti-rabbit minus and anti-goat plus) were mixed and diluted 1:5 in PBS with 
0.5% BSA, and pre-incubated for 20 min. Following two washes with PBS con-
taining 0.5% BSA, the coverslips were incubated with the PLA probe solution for 
1 h at 37 °C in a humidified chamber. Single-antibody and probes-only negative 
controls were performed for each antibody tested to confirm assay specificity. 
Coverslips were washed twice in wash buffer A for 5 min under gentle agitation, 
and incubated with 1× ligation solution supplemented with DNA ligase (1:40 
dilution) for 30 min at 37 °C in a humidified chamber. After two more washes in 
wash buffer A for 2 min with gentle agitation, coverslips were incubated with 1× 
amplification solution supplemented with DNA polymerase (1:80 dilution) for 1 h 
40 min at 37 °C in a humid chamber. Samples were protected from light from this 
step onwards. Following two washes in wash buffer B for 10 min, the coverslips 
were dried  overnight, and finally mounted on a microscope slide using Duolink 
In situ Mounting Medium with DAPI. Images of random fields of view were 
acquired using a LSM 700 confocal microscope (Leica) using a Plan-Apochromat 
40× /1.3 Oil DIC M27 objective, performing z-stack with optimal spacing (∼ 0.36 µ m). 
Images were analysed automatically using ImageJ. For this, nuclear (DAPI) and 
PLA z-stacks were first individually flattened (max intensity projection) and 
thresholded to remove background noise. Nuclear images were further segmented 
using the watershed function. Total nuclei and PLA spots were quantified using the 
‘analyse particle’ function of ImageJ, and nuclear PLA spots were quantified using 
the ‘speckle inspector’ function of the ImageJ plugin BioVoxxel.
RNA immunoprecipitation. Approximately 2 × 107 cells were used for each 
RNA immunoprecipitation (RIP). Unless stated otherwise, all biochemical steps 
were performed on ice or at 4 °C, and ice-cold buffers were supplemented with 
cOmplete Protease Inhibitors (Roche) and PhosSTOP Phosphatase Inhibitor 
Cocktail (Roche). Cells were fed with fresh culture medium 2 h before being 
washed once with room-temperature PBS and UV crosslinked in PBS at room 
temperature using a Stratalinker 1800 at 254 nm (400 mJ/cm2). Crosslinked cells 
were scraped off in cell-dissociation buffer (CDB, Gibco) and pelleted at 250g for 
5 min. The cell pellet was incubated in five volumes of isotonic lysis buffer (ILB; 
10 mM Tris-HCl pH 7.5, 3 mM CaCl2, 2 mM MgCl2, 0.32 M sucrose) for 12 min 
to induce cell swelling. Then, Triton X-100 was added to a final concentration of 
0.3%, and cells were incubated for 6 min to lyse the plasma membranes. Nuclei 
were pelleted at 600g for 5 min, washed once with ten volumes of ILB, and finally 
resuspended in two volumes of nuclear lysis buffer (NLB; 50 mM Tris-HCl pH 7.5, 
100 mM NaCl, 50 mM KCl, 3 mM MgCl2, 1 mM EDTA, 10% glycerol, 0.1% Tween) 
supplemented with 800 U/ml RNasin Ribonuclease Plus Inhibitor (Promega) and 
1 µ M DTT. The nuclear suspension was transferred to a Dounce homogenizer 
(Jencons Scientific) and homogenized by performing 70 strokes with a tight pestle. 
The nuclear lysate was incubated with rotation for 30 min, homogenized again by 
perfoming 30 additional strokes with the tight pestle, and incubated in rotation 
for 15 min at room temperature after addition of 12.5 µ g/ml of DNase I (Sigma). 
The protein concentration was assessed, and approximately 1 mg of protein was 
used for overnight immunoprecipitation with rotation with the primary anti-
body of interest (Supplementary Table 6), or with equal amounts of non-immune 
species-matched IgG. Ten per cent of the protein lysate used for immunoprecipi-
tation was saved as pre-immunoprecipitation input and stored at − 80 °C for sub-
sequent RNA extraction. Immunoprecipitation reactions were then incubated for 
1 h with 30 µ l of protein-G agarose, then washed twice with 1 ml of LiCl wash buffer 
(50 mM Tris-HCl pH 7.5, 250 mM LiCl, 0.1% Triton X-100, 1 mM DTT) and twice 
with 1 ml of NLB. Beads were resuspended in 90 µ l of 30 mM Tris-HCl pH 9.0, 
and DNase-digested using the RNase-free DNase kit (QIAGEN) by adding 10 µ l 
of RDD buffer and 2.5 µ l of DNase. The pre-immunoprecipitation input samples 
were similarly treated in parallel, and samples were incubated for 10 min at room 
temperature. The reaction was stopped by adding 2 mM EDTA and by heating at 
70 °C for 5 min. Proteins were digested by adding 2 µ l of proteinase K (20 mg/ml; 
Sigma-Aldrich) and by incubating at 37 °C for 30 min. Finally, RNA was extracted 
with 1 ml of TriReagent (Sigma-Aldrich) according to the supplier’s instructions. 
The RNA was resuspended in nuclease-free water, and half of the sample was used 
in a reverse-transcription reaction using SuperScript II (ThermoFisher) using the 
manufacturer’s protocol. The other half was used in a control reaction with no 
reverse transcriptase to confirm successful removal of DNA contaminants. Samples 
were quantified by quantitative real-time PCR (qPCR), and normalized first to 
the pre-immunoprecipitation input and then to the IgG control using the ∆ ∆ Ct 
approach (see below). Supplementary Table 5 shows the primers used.
Chromatin immunoprecipitation. Approximately 2 × 107 cells were used for each 
chromatin immunoprecipitation (ChIP), and cells were fed with fresh medium 2 h 
before collection. ChIP was performed using a previously described protocol10,30. 
Briefly, cells were crosslinked on plates, first with protein–protein  crosslinkers 
(10 mM dimethyl 3,3′ -dithiopropionimidate dihydrochloride and 2.5 mM 
3,3′ -dithiodipropionic acid di-N-hydroxysuccinimide ester; Sigma-Aldrich) for 
15 min at room temperature, then with 1% formaldehyde for 15 min. Crosslinking 
was quenched with glycine, after which cells were collected, subjected to nuclear 
extraction, and sonicated to fragment the DNA. Following pre-clearing, the lysate 
was incubated overnight with the antibodies of interest (Supplementary Table 6) 
or non-immune IgG. ChIP was completed by incubation with protein-G agarose 
beads followed by subsequent washes with high salt and LiCl-containing buffers 
(all exactly as previously described10,30). Crosslinking was reverted, first by  adding 
DTT (for disulfide bridge-containing protein–protein crosslinkers), then by incu-
bating in high salt at high temperature. DNA was finally purified by sequential 
phenol–chloroform and chloroform extractions. Samples were analysed by qPCR 
using the ∆ ∆ Ct approach (see Supplementary Table 5 for primer sequences). First, 
a region in the last exon of SMAD7 was used as internal control to normalize for 
background binding. Second, the enrichment was normalized to the the enrich-
ment observed in non-immune IgG ChIP controls.
m6A dot blot. m6A dot blots were performed as described with minor 
 modifications23. Poly-A RNA was purified from total cellular RNA using the 
Dynabeads mRNA Purification Kit (ThermoFisher), diluted in 50 µ l of RNA 
loading buffer (RLB; 2.2 M formaldehyde, 50% formamide, 0.5× MOPS buffer 
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(20 mM MOPS, 12.5 mM CH3COONa, 1.25 mM EDTA, pH 7.0)), incubated at 
55 °C for 15 min, and snap-cooled on ice. An Amersham Hybond-XL membrane 
was rehydrated in water for 3 min, then in 10× saline-sodium citrate buffer (SSC; 
1.5 M NaCl, 150 mM Na3C6H5O7, pH 7.0) for 10 min, and finally ‘sandwiched’ in 
a 96-well dot blot hybridization manifold (ThermoFisher Scientific). Following 
two washes of the wells with 150 µ l of 10× SSC, the RNA was spotted onto the 
membrane. After UV crosslinking for 2 min at 254 nm using a Stratalinker 1800 
(Stratagene), the membrane was washed once with Tris-buffered saline Tween 
buffer (TBST; 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween-20), and 
blocked for 1 h at room temperature with TBST supplemented with 4% non-fat 
dry milk. Incubations with the anti-m6A primary antibody (Synaptic Systems, 
202-111; used at 1 µ g/ml) and the mouse-HRP secondary antibody (Supplementary 
Table 6) were each performed in TBST with 4% milk for 1 h at room temerature, 
and were followed by three 10-min washes at room temperature in TBST. Finally, 
the membrane was incubated with ECL2 Western Blotting Substrate (Pierce), and 
exposed to X-Ray Super RX film.
m6A nuclear-enriched methylated RNA immunoprecipitation. m6A MeRIP 
of nuclear-enriched RNA for analysis by deep sequencing (NeMeRIP–seq) was 
 performed using modifications of previously described methods23,45. For each 
 sample, 7.5 × 107 hESCs were used, and three biological replicates were performed 
per condition. Cells were fed with fresh medium for 2 h before washing with PBS, 
scraping in cell dissociation buffer (CDB, Gibco), and pelleting at 250 g for 5 min. 
The cell pellet was incubated in five volumes of isotonic lysis buffer (ILB; 10 mM 
Tris-HCl pH 7.5, 3 mM CaCl2, 2 mM MgCl2, 0.32 M sucrose, 1,000 U/ml RNAsin 
RNase inhibitor (Promega), 1 mM DTT) for 10 min to induce cell swelling. Then, 
Triton X-100 was added to a final concentration of 0.3% and cells were incubated 
for 6 min to lyse the plasma membranes. Nuclei were pelleted at 600g for 5 min 
and washed once with ten volumes of ILB. RNA was extracted from the nuclear 
pellet using the RNeasy midi kit (QIAGEN) according to the manufacturer’s 
 instructions. Residual contaminating DNA was digested in solution using the 
RNase-free DNase set from QIAGEN, and RNA was re-purified by sequential acid 
phenol− chloroform and chloroform extractions followed by ethanol precipitation. 
At this stage, complete removal of DNA contamination was confirmed by qPCR of 
the resulting RNA without a reverse-transcription step. RNA was then chemically 
fragmented in 20 µ l reactions each containing 20 µ g of RNA in fragmentation buffer 
(10 mM ZnCl2, 10 mM Tris-HCl pH 7.0). Such reactions were incubated at 95 °C 
for 5 min, followed by inactivation with 50 mM EDTA and storage on ice. The 
fragmented RNA was then cleaned up by ethanol precipitation. In preparation 
for MeRIP, 15 µ g of anti-m6A antibody (Synaptic Systems, 202-003) or equivalent 
amounts of rabbit non-immune IgG were crosslinked to 0.5 mg of magnetic beads 
using the Dynabeads Antibody Coupling Kit (ThermoFisher Scientific)  according 
to the manufacturer’s instructions. Following equilibration of the magnetic beads 
by washing with 500 µ l of binding buffer (50 mM Tris-HCl pH 7.5, 150 mM 
NaCl2, 1% NP-40, 1 mM EDTA), MeRIP reactions were assembled with 300 µ g 
of the fragmented RNA in 3 ml of binding buffer supplemented with 3,000 U of 
RNAsin RNase inhibitor. Samples were incubated with rotation at 7 r.p.m. for 1 h 
at room temperature. Fragmented RNA (5 µ g, 10% of the amount used for MeRIP) 
was set aside as pre-MeRIP input control. MeRIP reactions were washed twice 
with binding buffer, once with low-salt buffer (LSB; 0.25× SSPE (saline-sodium 
 phosphate-EDTA buffer; 150 mM NaCl, 10 mM NaHPO4, 10 mM Na2-EDTA, 
pH 7.4), 37.5 mM NaCl2, 1 mM EDTA, 0.05% Tween-20), once with high-salt 
buffer (HSB; 0.25× SSPE, 137.5 mM NaCl2, 1 mM EDTA, 0.05% Tween-20), and 
twice with TE− Tween buffer (TTB; 10 mM Tris-HCl pH 7.4, 1 mM EDTA, 0.05% 
Tween-20). Each wash was performed by incubating the beads with 500 µ l of buffer 
at 7 r.p.m. for 3 min at room temperature. Finally, RNA was eluted from the beads 
by four successive incubations with 75 µ l of elution buffer (50 mM Tris-HCl pH 7.5, 
150 mM NaCl2, 20 mM DTT, 0.1% SDS, 1 mM EDTA) at 42 °C. Both the RNA from 
pooled MeRIP eluates and the pre-MeRIP input were purified and concentrated by 
sequential acid phenol–chloroform and chloroform extractions followed by ethanol 
precipitation. Glycogen (30 µ g) was added as carrier during ethanol precipitation. 
RNA was resuspended in 15 µ l of ultrapure RNase-free water. DNA libraries were 
prepared for deep sequencing using the TruSeq Stranded total RNA kit (Illumina) 
according to the manufacturer’s instructions with the following exceptions: 
(1) Ribo-Zero treatment was performed only for pre-NeMeRIP samples, as there 
was minimal ribosomal RNA contamination in m6A NeMeRIP samples; (2) since 
samples were pre-fragmented, the fragmentation step was bypassed and 30 ng of 
RNA from each sample was used directly for library prep; (3) owing to the small size 
of the library, a twofold excess of Ampure XP beads was used during all purification 
steps in order to retain small fragments; (4) owing to the presence of contami-
nating adapter dimers, the library was gel-extracted using gel-safe stain and a dark 
reader in order to remove fragments smaller than ∼ 120 bp. Pooled libraries were 
diluted and denatured for sequencing on the NextSeq 500 (Illumina) according 
to the manufacturer’s instructions. Samples were pooled to obtain > 30 million 
unique clusters per sample. The PhiX control library (Illumina) was spiked into 
the main library pool at 1% vol/vol for quality control purposes. Sequencing was 
performed using a high output flow cell with 2 × 75 cycles of sequencing, which 
provided ∼ 800 million paired-end reads from ∼ 400 million unique clusters from 
each lane. Overall, an average of ∼ 33 million and ∼ 54 million paired-end reads 
were generated for m6A MeRIP and pre-MeRIP samples, respectively.
m6A MeRIP samples to be analysed by qPCR (NeMeRIP–qPCR) were pro-
cessed as described for NeMeRIP–seq, but starting from 2.5 × 107 cells. MeRIP 
of cytoplasmic RNA was performed using RNA extracted from the cytoplasmic 
fraction of cells that were being processed for NeMeRIP. In both cases, MeRIP 
was performed as for NeMeRIP–seq, but using 2.5 µ g of anti-m6A antibody 
(or equivalent amounts of rabbit non-immune IgG) and 50 µ g RNA in 500 µ l 
 binding buffer supplemented with 500 U RNAsin RNase inhibitor. At the end of 
the protocol, the RNA was resuspended in 15 µ l ultrapure RNase-free water. For 
m6A MeRIP on total RNA, the protocol just described was followed exactly, with 
the exception that the subcellular fractionation step was bypassed, and that total 
RNA was extracted from 5 × 106 cells. For m6A MeRIP on mRNA, poly-A RNA was 
purified from 75 µ g total RNA using the Dynabeads mRNA Purification Kit, and 
2.5 µ g of the resulting mRNA was used for chemical fragmentation and subsequent 
MeRIP with 1 µ g anti-m6A antibody. At the end of all these protocols, cDNA syn-
thesis was performed using all of the MeRIP material in a 30 µ l reaction containing 
500 ng random primers, 0.5 mM dNTPs, 20 U RNaseOUT, and 200 U SuperScript II 
(all from Invitrogen) according to the manufacturer’s instructions. cDNA was 
diluted tenfold, and 5 µ l of this dilution was used for qPCR using KAPA Sybr Fast 
Low Rox (KAPA Biosystems). For each gene of interest, two primer pairs were 
designed against either the region containing the m6A peak23 or against a  negative 
region (a portion of the same transcript lacking the m6A peak; Supplementary 
Table 5). Results of MeRIP–qPCR for each gene were then calculated using the 
∆ ∆ Ct approach by using the negative region to normalize both for the expression 
level of the transcript of interest and for background binding.
Analysis of NeMeRIP–seq data. Quality of raw sequencing data was assessed 
using Trimmomatic v.0.3546, with parameters ‘LEADING:3 TRAILING:3 
SLIDINGWINDOW:5:10 MINLEN:40’. Reads were aligned to the GRCh38 
human genome assembly using TopHat 2.0.1347 with parameters ‘–library-type 
fr-firststrand –transcriptome-index’ and the Ensembl GRCh38.83 annotation. 
Identification of novel splice junctions was allowed. Paired-end and unpaired 
reads passing quality control were concatenated and mapped in ‘single-end’ 
mode in order to be used with MeTDiff48, which supports only single-end reads. 
Reads with MAPQ < 20 were filtered out. m6A peak calling and differential RNA 
 methylation in the exome were assessed using MetDiff48 with pooled inputs for 
each  condition, ‘GENE_ANNO_GTF = GRCh38.83, MINIMAL_MAPQ = 20’, 
and of the  remaining parameters as default (PEAK_CUTOFF_FDR = 0.05; DIFF_
PEAK_CUTOFF_FDR = 0.05). MetDiff calculates P values using a  likelihood 
ratio test, then adjusts them to FDR by Benjamini–Hochberg correction. An 
additional cut-off of absolute fold-change > 1.5 (meaning an absolute log2 fold-
change > 0.585) was applied for certain analyses as specified in the figure legends 
or tables. Given known differences between epitranscriptome maps as a  function 
of pipeline49,50, we confirmed the site-specific and general trends in our data 
by using an additional pipeline45. For this, MACS251 was used with parameters 
‘-q 0.05–nomodel–keep-dup all’ in m6A NeMeRIP–seq and paired inputs after 
read alignment with Bowtie 2.2.2.0 (reads with MAPQ < 20 were filtered out). 
Peaks found in at least two samples were kept for further processing, and a con-
sensus MACS2 peak list was obtained, merging those located within a distance 
less than 100 bp. The MetDiff and MACS2 peak lists largely overlapped (Extended 
Data Fig. 5d), and differed primarily because MACS2 identifies peaks throughout 
the genome while MetDiff identifies only peaks found on the exome (Extended 
Data Fig. 5c). For the following analyses focused on exonic m6A peaks, we consid-
ered a stringent consensus list of only those MetDiff peaks that overlapped with 
MACS2 peaks (Supplementary Table 2, ‘exon m6a’). We assessed the reproduci-
bility of m6A NeMeRIP–seq triplicates in peak regions using the Bioconductor 
package fCCAC v1.0.052. Hierarchical clustering (Euclidean distance, complete 
method) of F values corresponding to the first two canonical correlations divided 
the samples into activin and SB431542 clusters. Normalized read-coverage files 
were generated using the function 'normalize_bigwig' in RSeQC-2.653 with default 
parameters. The distribution of m6A coverage across genomic features was plotted 
using the Bioconductor package RCAS54 with sampleN = 0 (no downsampling) 
and  flankSize = 2500. Motif finding on m6A peaks was performed using DREME 
with default parameters55. For visualization purposes, the three biological replicates 
were combined. The Biodalliance genome viewer56 was used to generate figures. 
Gene expression in this experiment was estimated from the pre-MeRIP input 
samples (which represent an RNA-seq sample on nuclear-enriched RNA species). 
Quantification, normalization of read counts and estimation of differential gene 
expression in pre-MeRIP input samples were performed using featureCounts57 
© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
LETTER RESEARCH
and DESeq258. For assessment of reproducibility, regularized log transformation 
of count data was computed, and biological replicates of input samples of the 
same condition were clustered together in the PC space59. Estimation of differ-
ential m6A deposition onto each peak in NeMeRIP samples versus input controls 
was performed using an analogous approach. Functional-enrichment analysis of 
m6A-marked transcripts was performed using Enrichr44, as described above for 
mass-spectrometry data. The coordinates of SMAD2/3 ChIP–seq peaks in hESCs30 
were transferred from their original mappings on hg18 to hg38 using liftOver. 
Overlap of the resulting intervals with m6A peaks significantly downregulated after 
2 h of SB431542 treatment was determined using GAT60 with default parameters. 
SMAD2/3-binding sites were assigned to the nearest gene using the annotatePeaks.
pl function from the HOMER suite61 with standard parameters. The significance 
in the overlap between the resulting gene list and that of genes encoding for tran-
scripts with m6A peaks that are significantly downregulated after 2 h of SB431542 
treatment was calculated by a hypergeometric test where the population size corre-
sponded to the number of genes in the standard Ensembl annotation (GRCh38.83).
m6A peaks on introns were identified in three steps (Extended Data Fig. 6d). 
First, MetDiff was used to simultaneously perform peak calling and differential 
methylation analysis. Since MetDiff only accepts a transcriptome GTF annotation 
as an input to determine the genomic space onto which it identifies m6A peaks, 
in order to determine peaks on introns, we followed the strategy recommended 
by the package developers of running the software using a custom transcriptome 
annotation that includes introns48,62. This ‘extended’ transcriptome annotation 
was built using Cufflinks 2.2.163 with parameters ‘–library-type = fr-firststrand -m 
100 -s 50’ and guided by the Ensembl annotation (GRCh38.83). This was assem-
bled using all available pre-NeMeRIP input reads. The result was an extended 
transcriptome annotation including all of the transcribed genome that could be 
detected and reconstructed from our nuclear-enriched input RNA samples, thus 
including most expressed introns. Then, MetDiff was run using this extended 
annotation as input for GENE_ANNO_GTF, pooled inputs for each condition, 
WINDOW_WIDTH = 40, SLIDING_STEP = 20, FRAGMENT_LENGHT = 250, 
PEAK_CUTOFF_PVALUE = 1E-03, FOLD_ENRICHMENT = 2, MINIMAL_
MAPQ = 20, and all other parameters as default. In a second step, the peaks iden-
tified by MetDiff were filtered for robustness by requiring that they overlapped 
with MACS2 peak calls, exactly as for exome-focused MetDiff peak calls (Extended 
Data Fig. 5d). Finally, only peaks that strictly did not overlap with any exon based 
on the Human Gencode annotation V.27 were retained to ensure specificity of 
mapping to introns (Supplementary Table 2; ‘intron m6A’). MetDiff scores for the 
resulting peak list were used to assess differential m6A deposition based on the 
cutoff of FDR < 0.05.
m6A exon peaks spanning splice sites were selected from those identified by 
both the MetDiff analysis on the transcribed genome that was just described and 
by MACS2. Among these peaks, those presenting sequencing reads that over-
lap both an exon and an upstream or downstream intron were further selected 
(Supplementary Table 2; ‘splice-site spanning m6A’). Peaks accomplishing MetDiff-
calculated FDR < 0.05 and absolute fold-change > 1.5 (log2 fold-change < − 0.585) 
were used to create densities of RPKM-normalized reads inside exons and in the 
± 500 bp surrounding introns. Biological replicates were merged and depicted 
on 10 bp-binned heatmaps for visualization purposes. To study the covariation 
of m6A peaks inside each transcriptional unit, the exonic peak with the greatest 
downregulated MetDiff fold-change was compared to the mean fold-change of the 
rest of the m6A peaks found within the gene (both on exons and on introns). The 
resulting correlation was significant (P < 2 × 10−16; adjusted R2 = 0.2221)
RNA sequencing. Poly-A purified opposing-strand-specific mRNA libraries were 
prepared from 200 ng of total RNA using the TruSeq Stranded mRNA HT sample 
preparation kit (Illumina). Samples were individually indexed for pooling using a 
dual-index strategy. Libraries were quantified both with a Qubit (ThermoFisher 
Scientific) and by qPCR using the NGS Library Quantification Kit (KAPA 
Biosystems). Libraries were then normalized and pooled. Pooled libraries were 
diluted and denatured for sequencing on the NextSeq 500 (Illumina) according to 
the manufacturer’s instructions. Samples were pooled so as to obtain > 30 million 
unique clusters per sample (18 samples were split in two runs and multiplexed 
across four lanes per run). The PhiX control library (Illumina) was spiked into 
the main library pool at 1% vol/vol for quality control purposes. Sequencing was 
performed using a high-output flow cell with 2 × 75 cycles of sequencing, which 
provided ∼ 800 million paired-end reads from ∼ 400 million unique clusters from 
each run. Overall, a total of ∼ 80 million paired-end reads per sample were obtained.
Analysis of RNA-seq data. Reads were trimmed using Sickle64 with ‘q = 20 and 
l = 30’. To prepare for reads alignment, the human transcriptome was built with 
TopHat2 v.2.1.044 based on Bowtie v.2.2.665 by using the human GRCh38.p6 as 
reference genome, and the Ensembl gene transfer format (GTF) as annotation 
(http://ftp.ensembl.org/pub/release-83/gtf/homo_sapiens/). All analyses were 
performed using this transcriptome assembly. Alignment was performed using 
TopHat2 with standard parameters. Using Samtools view66, reads with MAPQ 
> 10 were kept for further analyses. Subsequent quantitative data analysis was 
performed using SeqMonk67. The RNA-seq pipeline was used to quantify gene 
expression as reads per million mapped reads (RPM), and differential expression 
analysis for binary comparisons was performed using the R package DESeq258. 
A combined cut-off of negative binomial test P < 0.05 and abs.FC > 2 was  chosen. 
Analysis of differentially expressed transcripts across all samples was done 
using the Bioconductor timecourse package68 in R. The Hotelling T2 score for 
each transcript was calculated using the MB.2D function with all parameters set 
to their default value. Hotelling T2 scores were used to rank probes according 
to differential expression across the time course, and the top 5% differentially 
expressed transcripts were selected for complete Euclidean hierarchical clustering 
(k-means preprocessing; max of 300 clusters) using Perseus software. Z-scores 
of log2 normalized expression values across the timecourse were calculated and 
used for this analysis. Eight gene clusters were defined, and gene-enrichment 
analysis for selected clusters was performed using the Fisher’s exact test imple-
mented in Enrichr44. Only enriched terms with a Benjamini–Hochberg adjusted 
P value < 0.05 were considered. Principal component analysis was performed on 
the same list of top 5% differentially expressed transcripts using Perseus.
Quantitative real-time PCR. Cellular RNA was extracted using the GenElute 
Mammalian Total RNA Miniprep Kit and the On-Column DNase I Digestion 
Set (both from Sigma-Aldrich) following the manufacturer’s instructions. 500 ng 
of RNA was used for complementary DNA (cDNA) synthesis using SuperScript 
II (Invitrogen) according to the manufacturer’s instructions. cDNA was diluted 
30-fold, and 5 µ l was used for qPCR with SensiMix SYBR low-ROX (Bioline) and 
150 nM forward and reverse primers (Sigma-Aldrich; see Supplementary Table 5 
for primer sequences). Samples were run as technical duplicates in 96-well plates 
on a Stratagene Mx-3005P (Agilent), and results were analysed using the delta-delta 
cycle threshold (∆ ∆ Ct) approach69 using RPLP0 as housekeeping gene. The 
reference sample used as control to calculate the relative gene expression is indi-
cated in each figure or figure legend. In cases where multiple control samples were 
used as reference, the average ∆ Ct from all controls was used when calculating the 
∆ ∆ Ct. All primers were designed using PrimerBlast (http://www.ncbi.nlm.nih.
gov/tools/primer-blast/), and were validated to have a qPCR efficiency > 98% and 
to produce a single PCR product.
mRNA-stability measurements. RNA stability was measured by collecting 
RNA samples at different time points following transcriptional inhibition with 
1 µ g/ml actinomycin D (Sigma-Aldrich). Following qPCR analyses using equal 
amounts of mRNA, gene expression was expressed as relative to the beginning of 
the  experiment (no actinomycin D treatment). The data were then fitted to a one-
phase decay-regression model70, and statistical differences in mRNA half-life were 
evaluated by comparing the model fits by extra sum-of-squares F test.
Western blots. Samples were prepared by adding Laemmli buffer (final concen-
trations: 30 mM Tris-HCl pH 6.8, 6% glycerol, 2% SDS, 0.02% bromophenol blue 
and 0.25% β -mercaptoethanol), and were denatured at 95 °C for 5 min. Proteins 
were loaded and run on 4–12% NuPAGE Bis-Tris Precast Gels (Invitrogen), then 
transferred to polyvinylidene fluoride (PVDF) membranes by liquid transfer using 
NuPAGE Transfer buffer (Invitrogen). Membranes were blocked for 1 h at room 
temperature in PBS, 0.05% Tween-20 (PBST) supplemented with 4% non-fat dried 
milk, and incubated overnight at 4 °C with primary antibody diluted in the same 
blocking buffer (Supplementary Table 6). After three washes in PBST, membranes 
were incubated for 1 h at room temperature with horseradish peroxidase (HRP)-
conjugated secondary antibodies diluted in blocking buffer (Supplementary 
Table 6), then washed a further three times with PBST before incubation with 
Pierce ECL2 Western Blotting Substrate (Thermo) and exposure with X-Ray Super 
RX Films (Fujifilm).
Immunofluorescence. Cells were fixed for 20 min at 4 °C in PBS with 4% PFA, 
rinsed three times with PBS, and blocked and permeabilized for 30 min at room 
temperature using PBS with 10% donkey serum (Biorad) and 0.1% Triton X-100 
(Sigma-Aldrich). Primary antibodies (Supplementary Table 6) were diluted in 
PBS with 1% donkey serum and 0.1% Triton X-100 and incubated overnight 
at 4 °C. This was followed by three washes with PBS and further incubation 
with AlexaFluor secondary antibodies (Supplementary Table 6) for 1 h at room 
 temperature away from light. Cells were finally washed three times with PBS, and 
DAPI (Sigma-Aldrich) was added to the first wash to stain nuclei. Images were 
acquired using a LSM 700 confocal microscope (Leica).
Flow cytometry. Single-cell suspensions were prepared by incubation in cell–
cell dissociation buffer (CDB; Gibco) for 10 min at 37 °C followed by extensive 
 pipetting. Cells were washed twice with PBS and fixed for 20 min at 4 °C with PBS, 
4% PFA. After three washes with PBS, cells were first permeabilized for 20 min at 
room temperature with PBS, 0.1% Triton X-100, then blocked for 30 min at room 
temperature with PBS containing 10% donkey serum. Primary and secondary 
antibody incubations (Supplementary Table 6) were performed for 1 h each at 
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room temperature in PBS, 1% donkey serum, 0.1% Triton X-100, and cells were 
washed three times with this same buffer after each incubation. Flow cytometry 
was performed using a Cyan ADP flow cytometer, and at least 10,000 events were 
recorded. Data analysis was performed using FlowJo X.
Statistics and reproducibility. Unless described otherwise in a specific section of 
the Methods, standard statistical analyses were performed using GraphPad Prism 
7 using default parameters. The type and number of replicates, the  statistical 
test used, and the test results are described in the figure legends. The level of 
significance in all graphs is represented as follows: * P < 0.05, * * P < 0.01 and 
* * * P < 0.001. Test assumptions (for example, normal distribution) were confirmed 
where appropriate. For analyses with n < 10, individual data points are shown, and 
the mean ± s.e.m. is reported for all analyses with n > 2. The mean is reported 
when n = 2, and no other statistics were calculated for these experiments owing to 
the small sample size. No experimental samples were excluded from the statistical 
analyses. Sample size was not pre-determined through power calculations, and 
no randomization or investigator blinding approaches were implemented during 
the experiments and data analyses. When representative results are presented, the 
experiments were reproduced in at least two independent cultures, and the exact 
number of such replications is detailed in the figure legend.
Code availability. Custom bioinformatics scripts used to analyse the data 
 presented in the study have been deposited in GitHub (http://github.com/pmb59/
neMeRIP-seq).
Data availability. The mass-spectrometry proteomics data that support the 
 findings of this study have been deposited to the ProteomeXchange Consortium 
via the PRIDE partner repository with the identifier PXD005285. Nucleotide 
sequencing data that support the findings of this study have been deposited to 
Array Express with identifiers E-MTAB-5229 and E-MTAB-5230. Source Data for 
the graphical representations found in all figures and Extended Data figures are 
provided in the Supplementary Information of this manuscript. Electrophoretic 
gel Source Data (uncropped scans with size marker indications) are presented 
in Supplementary Fig. 1. Supplementary Tables 1 to 4 provide the results of 
 bioinformatics analyses described in the text and figure legends. All other data 
that support the findings of this study are available from the corresponding author 
upon reasonable request.
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Extended Data Figure 1 | See next page for caption.
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Extended Data Figure 1 | Optimized co-immunoprecipitation protocol 
to define the SMAD2/3 interactome in hPSCs and early endoderm cells. 
a, Western blots of SMAD2/3 or control (IgG) immunoprecipitations 
from nuclear extracts of hESCs following the co-IP1 or co-IP2 protocols. 
Input is 5% of the material used for immunoprecipitations. Results are 
representative of two independent experiments. For gel Source Data, 
see Supplementary Fig. 1. b, Scatter plots of the log2 ratios of label-free 
quantification (LFQ) intensities for proteins identified by quantitative 
mass spectrometry in SMAD2/3 co-immunoprecipitations compared 
with IgG negative control co-immunoprecipitations. The experiments 
were performed from nuclear extracts of hESCs. The SMAD2/3 and IgG 
negative control co-immunoprecipitations were differentially labelled after 
immunoprecipitation using the dimethyl method, followed by a combined 
run of the two samples in order to compare the abundance of specific 
peptides and identify enriched peptides. The values for technical dye-swap 
duplicates are plotted on different axes, and proteins whose enrichment 
was significant (significance B < 0.01) are shown in black and named. 
As a result of this comparison between the two co-immunoprecipitation 
protocols, co-IP2 was selected for further experiments (see Supplementary 
Discussion). c, Volcano plots of statistical significance against fold-change 
for proteins identified by label-free quantitative mass spectrometry in 
SMAD2/3 or IgG negative control immunoprecipitations in pluripotent 
hESCs or early endoderm (see Fig. 1a). The black lines indicate the 
threshold used to determine specific SMAD2/3 interactors, which are 
located to the right (n = 3 co-immunoprecipitations; one-tailed t-test: 
permutation-based FDR < 0.05). d, Selected results of the analysis 
described in c for SMAD2, SMAD3 and selected known bona fide 
SMAD2/3-binding partners (full results can be found in Supplementary 
Table 1). e, Mean label-free quantification (LFQ) intensity log2 ratios 
in endoderm (endo) and pluripotent cells (pluri) for all SMAD2/3 
interactors. Differentially enriched proteins are shown as green and blue 
bars. f, Selected results from gene ontology (GO) enrichment analysis, 
and enrichment analysis for mouse phenotypes annotated in the MGI 
database. All putative SMAD2/3-interacting proteins were considered for 
this analysis (n = 89 proteins; Fisher’s exact test followed by Benjamini–
Hochberg correction for multiple comparisons). For each term, its rank in 
the analysis, the adjusted P value, and the number of associated genes are 
reported.
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Extended Data Figure 2 | See next page for caption.
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Extended Data Figure 2 | Functional characterization of transcriptional 
and epigenetic cofactors of SMAD2/3 in hPSCs. a, Western blots of 
SMAD2/3 or control (IgG) immunoprecipitations from nuclear extracts 
of pluripotent hESCs (pluri) or hESCs differentiated into endoderm for 
36 h (endo). Input is 5% of the material used for immunoprecipitations. 
Results are representative of two independent experiments. b, Schematic 
of the experimental approach for the generation of iKD hESC lines for 
SMAD2/3 cofactors. c, qPCR screening of iKD hESCs cultured in the 
absence (CTR) or presence (TET) of tetracycline for three days. Three 
distinct shRNAs were tested for each gene. Expression is normalized to 
the mean level in hESCs carrying negative control shRNAs (scrambled 
(SCR) or against B2M) and cultured in the absence of tetracycline. The 
mean is indicated, n = 2 independent clonal pools. Note than for the 
B2M shRNA only the scrambled shRNA was used as negative control. 
shRNAs selected for further experiments are circled. d, Phase-contrast 
images of iKD hESCs expressing the indicated shRNAs (sh) and cultured 
in the presence of tetracycline for six days to induce knockdown. Scale 
bars, 400 µ m. Results are representative of two independent experiments. 
e, Immunofluorescence for the pluripotency factor NANOG in iKD 
hESCs for the indicated genes cultured in the absence (CTR) or presence 
of tetracycline (TET) for six days. Scale bars, 400 µ m. Results are 
representative of two independent experiments. f, Heat map summarizing 
qPCR analyses of iKD hESCs cultured as in e. log2 fold-changes (FC) 
are compared to scrambled control (n = 2 clonal pools). Germ-layer 
markers are grouped in boxes: green, endoderm; red, mesoderm; blue, 
neuroectoderm.
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Extended Data Figure 3 | Functional characterization of transcriptional 
and epigenetic cofactors of SMAD2/3 during endoderm differentiation. 
a, qPCR validation of iKD hESCs in pluripotent cells (PLURI) or following 
endoderm differentiation (ENDO). Pluripotent cells were cultured 
in the absence (CTR) or presence (TET) of tetracycline for six days. 
For endoderm differentiation, tetracycline treatment was initiated in 
undifferentiated hESCs for three days in order to ensure gene knockdown 
at the start of endoderm specification, and was then maintained during 
differentiation (three days). For each gene, the shRNA resulting in the 
strongest level of knockdown in hPSCs was selected (refer to Extended 
Data Fig. 2). Expression is normalized to the mean level in pluripotent 
hESCs carrying scrambled control shRNA and cultured in the absence 
of tetracycline. The mean is indicated, n = 2 independent clonal pools. 
b, Immunofluorescence of the endoderm marker SOX17 following 
endoderm differentiation of iKD hESCs expressing the indicated 
shRNAs and cultured as described in a. Scale bars, 400 µ m. Results are 
representative of two independent experiments. c, qPCR following 
endoderm differentiation of iKD hESCs. The mean is indicated, n = 2 
independent clonal pools. d, Table summarizing the phenotypic results 
presented in Extended Data Fig. 2 and in this figure. E, endoderm;  
N, neuroectoderm; M, mesoderm.
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Extended Data Figure 4 | Mechanistic insights into the functional 
interaction between SMAD2/3 and the m6A methyltransferase complex. 
a–c, Western blots of SMAD2/3, METTL3, METTL14 or control (IgG) 
immunoprecipitations from nuclear extracts of hESCs (a, c) or hiPSCs (b).  
Input is 5% of the material used for immunoprecipitations. In c, 
immunoprecipitations were performed from hPSCs maintained in the 
presence of activin or treated for 1 h with the activin–NODAL signalling 
inhibitor SB431542. Results are representative of three (a) or two (b, c) 
independent experiments. d, qPCR validation of hESCs constitutively 
overexpressing NANOG (NANOG OE) following gene targeting of the 
AAVS1 locus with pAAV-Puro_CAG-NANOG. Parental wild-type H9 
hESCs (H9) were analysed as negative controls. Cells were cultured in 
the presence of activin or treated with SB431542 for the indicated times. 
The mean is shown, n = 2 cultures. NANOG-overexpressing cells are 
resistant to downregulation of NANOG following inhibiton of activin–
NODAL signalling. e, RNA immunoprecipitation experiments for WTAP, 
SMAD2/3 or IgG control in NANOG-overexpressing hESCs maintained 
in the presence of activin or treated for 2 h with SB431542. Enrichment of 
the indicated transcripts was measured by qPCR and expressed relative to 
background levels observed in control IgG RNA immunoprecipitations in 
the presence of activin. RPLP0 was tested as a negative control transcript. 
Mean ± s.e.m., n = 3 cultures. Significance of differences from activin (left) 
or IgG (right) RIP was tested by two-way ANOVA with post hoc Holm–
Sidak comparisons. f, ChIP–qPCR in hESCs for ChIP against the indicated 
proteins or the negative control ChIP (IgG). qPCR was performed for 
validated genomic SMAD2/3-binding sites associated with the indicated 
genes10,30. hESCs were cultured in the presence of activin or treated for 2 h 
with SB431542. Enrichment is normalized against background binding 
observed with IgG ChIP. The mean is shown, n = 2 technical replicates. 
Results are representative of three independent experiments.
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Extended Data Figure 5 | Monitoring changes in m6A deposition 
that are rapidly induced by inhibition of activin–NODAL signalling. 
a, b, MeRIP–qPCR results from purified mRNA, total cellular RNA or 
cellular RNA species separated by nuclear and cytoplasmic subcellular 
fractionation. hESCs were cultured in pluripotency-maintaining 
conditions containing activin or in conditions in which activin–NODAL 
signalling was inhibited for 2 h with SB431542. IgG MeRIP experiments 
were performed as negative controls. The mean is indicated, n = 2 
technical replicates. Differences between activin- and SB431542-treated 
cells were observed only in the nuclear-enriched fraction. Therefore, the 
nuclear-enriched MeRIP protocol (NeMeRIP) was used for subsequent 
experiments (refer to the Supplementary Discussion). Results are 
representative of two independent experiments. c, Overlap with the 
indicated genomic features of m6A peaks identified by NeMeRIP–seq 
using two different bioinformatics pipelines in which peak calling was 
performed using MetDiff or MACS2. For each pipeline, the analyses 
were performed on the union of peaks identified from data obtained in 
hESCs cultured in the presence of activin or with inhibition of activin–
NODAL signalling for 2 h with SB431542 (n = 3 cultures). Note that the 
sum of the percentages within each graph is not 100% because some 
m6A peaks overlap several feature types. MetDiff is an exome peak 
caller, and, accordingly, 100% of peaks map to exons. MACS2 identifies 
peaks throughout the genome. d, Venn diagrams showing the overlap of 
peaks identified by the two pipelines. Only MetDiff peaks that were also 
identified by MACS2 were considered for subsequent analyses focused on 
m6A peaks on exons. e, Top sequence motifs identified de novo on all m6A 
exon peaks, or on those that showed significant downregulation following 
inhibition of activin–NODAL signalling (activin–NODAL-sensitive m6A 
peaks; Supplementary Table 2). The position of the methylated adenosine 
is indicated by a box. f, Coverage profiles for all m6A exon peaks across 
the length of different genomic features. Each feature type is expressed 
as 100 bins of equal length with 5′ to 3′ directionality. g, h, Overlap of 
m6A exon peaks and transcription start sites (TSS) or transcription end 
sites (TES). In g, the analysis was performed for all m6A peaks. In h, 
only activin–NODAL-sensitive peaks were considered. i, Left, activin–
NODAL-sensitive m6A exon peaks were evaluated for direct overlap 
with SMAD2/3-binding sites as indicated by ChIP–seq30. n = 482 peaks; 
FDR = 0.41 as calculated by the permutation test implemented by the GAT 
python package; N.S., not significant based on 95% confidence interval. 
Right, overlap was calculated after the same features were mapped to 
their corresponding transcripts or genes, respectively. n = 372 genes; 
hypergeometric test P = 2.88 × 10−18, significant based on 95% confidence 
interval. j, m6A NeMeRIP–seq results for selected transcripts (n = 3 
cultures; replicates combined for visualization). Coverage tracks represent 
read enrichments normalized by million mapped reads and size of the 
library. Blue, sequencing results of m6A NeMeRIP; orange, sequencing 
results of pre-NeMeRIP input RNA (negative control). GENCODE gene 
annotations are shown (red, protein coding exons; white, untranslated 
exons; all potential exons are shown and overlaid). The location of 
SMAD2/3 ChIP–seq-binding sites is also shown. Compared to the other 
genes shown, m6A levels on SOX2 were unaffected by inhibition of 
activin–NODAL signalling, showing specificity of action. POU5F1 (also 
known as OCT4) is used as a negative control since it is known to not have 
a m6A site23, as confirmed by the lack of m6A enrichment compared to the 
input.
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Extended Data Figure 6 | Features of activin–NODAL-sensitive 
differential m6A deposition. a, Scatter plot of the average log2 fold-
change in SB431542 versus activin-treated hESCs for m6A NeMeRIP–seq 
and pre-NeMeRIP input RNA (n = 3 cultures). The analysis was performed 
for all m6A exon peaks (left), or for those peaks that were significantly 
downregulated following inhibition of activin–NODAL signalling (right). 
Data are colour coded according to the square of the difference between 
the two values (square diff.). b, c, As Extended Data Fig. 5j, but for 
representative transcripts that are stably expressed following inhibition 
of activin–NODAL signalling for 2 h (n = 3 cultures; replicates combined 
for visualization). The m6A NeMeRIP and input tracks were separated 
and are shown at different scales to facilitate comparison between the 
conditions. The m6A peaks and those significantly downregulated after 
2 h of SB431542 treatment are indicated. d, Venn diagram illustrating 
the strategy for identification of m6A peaks on introns. Peaks mapping 
to the transcribed genome were obtained by running MetDiff using an 
extended transcriptome annotation based on the pre-NeMeRIP input 
RNA, which has a high abundance of introns. The resulting peaks were 
first filtered by overlap with genome-wide MACS2-identified peaks, 
and then by lack of overlap with annotated exons. e, Results of MetDiff 
differential methylation analysis in activin versus 2 h SB431542 treatment 
for m6A peaks on introns. n = 3 cultures; P value calculated by likelihood 
ratio test implemented in the MetDiff R package, and adjusted to FDR by 
Benjamini–Hochberg correction. See Supplementary Table 2 for the FDR 
of individual peaks. Abs.FC, absolute fold-change. f, As Extended Data  
Fig. 5j, but for a representative transcript that shows activin–NODAL-
sensitive m6A deposition in introns (n = 3 cultures; replicates combined 
for visualization). The m6A peaks on exons, introns, and those 
significantly downregulated after SB431542 treatment within each subset 
are indicated. g, Plots of RPKM-normalized mean m6A coverage for 
m6A exon peaks significantly downregulated after SB431542 treatment 
(absolute fold-change > 1.5). Data for all such peaks is in blue, whereas 
green lines report coverage for only those peaks characterized by next 
generation sequencing reads that span exon–intron junctions. Exons were 
scaled proportionally, and the positions of the 3′ and 5′ splice sites (SS) are 
indicated. A window of 500 bp on either side of the splice sites is shown. 
m6A, signal from m6A NeMeRIP–seq; input, signal from pre-NeMeRIP 
input RNA. The results show that coverage of activin–NODAL-sensitive 
m6A peaks often spans across splice sites (highlighted by the dotted 
lines). h, Heat map representing in an extended form the data shown in 
g for all activin–NODAL-sensitive m6A exon peaks in hESCs cultured in 
the presence of activin. There are multiple regions in which sequencing 
coverage extends across exon–intron junctions (see Supplementary 
Table 2). i, Example of an activin–NODAL-sensitive peak located in 
the proximity of a 3′ splice site (n = 3 cultures; replicates combined for 
visualization). This peak is shown within its genomic context in c, where 
it is indicated by a dotted box. Top, m6A NeMeRIP–seq coverage; bottom, 
individual next generation sequencing reads. Multiple reads span the 
exon–intron junction (indicated by the dashed line). j, Relationship 
between the decrease of m6A on the most affected exonic peak located on 
a transcript (y axis) and the mean change of all other peaks mapping to the 
same transcript (x axis). The analysis considered transcripts with multiple 
m6A peaks and with at least one peak significantly decreasing after 
inhibition of activin–NODAL signalling with SB431542 (absolute fold-
change > 1.5). Sensitivity of m6A deposition to activin–NODAL signalling 
across these transcripts is correlated.
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Extended Data Figure 7 | Generation and functional characterization 
of hPSCs following iKD of the subunits of the m6A methyltransferase 
complex. a, qPCR validation of iKD hESCs cultured in the presence of 
tetracycline for five days (TET) to drive gene knockdown. Two distinct 
shRNAs and multiple clonal sublines (cl) were tested for each gene. 
Expression is normalized to the mean level in hESCs carrying a negative 
control scrambled (SCR) shRNA. For each gene, sh1 cl1 was selected for 
further analyses. The mean is indicated, n = 2 cultures. b, Western blot 
validation of selected iKD hESCs for the indicated genes. TUB4A4  
(α -tubulin), loading control. Results are representative of three 
independent experiments. c, MeRIP–qPCR in iKD hESCs cultured for 
ten days in the absence (CTR) or presence of tetracycline (TET). m6A 
abundance is shown relative to control conditions in the same hESC line. 
The mean is shown, n = 2 technical replicates. Results are representative 
of two independent experiments. d, m6A dot blot in WTAP or scramble 
shRNA control iKD hESCs treated as described in c. Decreasing amounts 
of mRNA were spotted to allow semiquantitative comparisons, as 
indicated. Results are representative of two independent experiments. 
e, Immunofluorescence of the pluripotency markers NANOG and 
OCT4 in iKD hESCs cultured for three passages (15 days) in the absence 
(CTR) or presence of tetracycline (TET). Scale bars, 100 µ m. Results are 
representative of two independent experiments. f, Flow cytometry showing 
NANOG expression in cells treated as in e. The percentage and median 
fluorescence intensity (MFI) of NANOG-positive cells (NANOG+) are 
shown. The gates used for the analysis are indicated, and were determined 
on the basis of a secondary-antibody-only negative staining (NEG). 
Results are representative of two independent experiments.
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Extended Data Figure 8 | Function of the m6A methyltransferase 
complex during germ-layer specification. a, qPCR analysis following 
neuroectoderm or endoderm differentiation of iKD hESCs cultured in 
absence (CTR) or presence of tetracycline (TET). Tetracycline treatment 
was initiated in undifferentiated hESCs for ten days and was maintained 
during differentiation (three days). Expression was normalized against 
the mean level in undifferentiated hESCs. Mean ± s.e.m., n = 3 cultures. 
Significant differences versus the same iKD line in control conditions were 
calculated by two-way ANOVA with post hoc Holm–Sidak comparisons. 
b, Flow cytometry quantification of the percentage of SOX1-positive 
cells (SOX1+) in cells treated as in a. Mean is shown, n = 2 cultures. 
c, Immunofluorescence of the lineage marker SOX17 in endoderm-
differentiated hESCs treated as in a. Scale bars, 100µ m. Results are 
representative of two independent experiments. d, qPCR validation of 
multiple inducible knockdown (MiKD) hESCs simultaneously expressing 
shRNAs against WTAP, METTL3 and METTL14. Cells expressing three 
copies of the scrambled shRNA (SCR3× ) were used as negative control. 
Cells were cultured in the presence of tetracycline (TET) for five days 
to drive gene knockdown. Mean ± s.e.m., n = 3 cultures. Significant 
differences versus SCR3× hESCs in control conditions were calculated 
by two-way ANOVA with post hoc Holm–Sidak comparisons. e, f, qPCR 
analysis following endoderm differentiation of WTAP, METTL3 and 
METTL14-MiKD hESCs treated as described in a. Mean ± s.e.m., n = 3 
cultures. Significant differences versus control conditions were calculated 
by two tailed t-test (e) or two-way ANOVA with post hoc Holm–Sidak 
comparisons (f).
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Extended Data Figure 9 | Function of the m6A methyltransferase 
complex during exit from pluripotency induced by inhibition of 
activin–NODAL signalling. a, qPCR analyses in iKD hESCs cultured 
in absence (CTR) or presence (TET) of tetracycline for ten days, then 
subjected to inhibition of activin–NODAL signalling with SB431542 
(SB) for the indicated time (see Extended Data Fig. 10a). Activin, cells 
maintained in standard pluripotency-promoting culture conditions 
containing activin and collected at the beginning of the experiment. 
Mean ± s.e.m., n = 3 cultures. Significant differences versus same iKD line 
in control conditions were calculated by two-way ANOVA with post hoc 
Holm–Sidak comparisons. b, Western blots of cells treated as described in 
a. TUBA4A, loading control. Results are representative of two independent 
experiments. c, Measurement of mRNA stability in WTAP iKD hESCs 
cultured in absence (CTR) or presence (TET) of tetracycline for ten 
days. Samples were collected following transcriptional inhibition using 
actinomycin D (ActD) for the indicated time. The statistical significance 
of differences between the mRNA half lives in tetracycline versus control 
is shown (n = 3 cultures, comparison of fits to one-phase decay model 
by extra sum-of-squares F-test). The difference was significant for 
NANOG but not for SOX2 (95% confidence interval). d, Model showing 
the interplays between activin–NODAL signalling and m6A deposition 
in hPSCs (left), and the phenotype induced by impairment of the m6A 
methyltransferase complex (right).
© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
LETTERRESEARCH
Extended Data Figure 10 | See next page for caption.
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Extended Data Figure 10 | Genome-wide analysis of the relationship 
between WTAP and activin–NODAL signalling. a, Schematic of the 
experimental approach to investigate the transcriptional changes induced 
by the knockdown of the m6A methyltransferase complex subunits during 
neuroectoderm specification of hESCs. b, qPCR analyses of WTAP iKD 
hESCs subjected to the experiment outlined in a (n = 3 cultures). Activin, 
cells maintained in standard pluripotency-promoting culture conditions 
containing activin and collected at the beginning of the experiment.  
Z-scores indicate differential expression measured in number of standard 
deviations from the mean across all time points. c, RNA-seq analysis at 
selected time points from the samples shown in panel b (n = 3 cultures). 
The heat map shows Z-scores for the top 5% differentially expressed genes 
(1789 genes as ranked by the Hotelling T2 statistic). Genes and samples 
were clustered based on their Euclidean distance, and the four major gene 
clusters are indicated (see Supplementary Discussion). d, Expression 
profiles of genes belonging to the clusters indicated in c. Selected results 
of gene-enrichment analysis and representative genes for each cluster 
are shown (cluster 1: n = 456 genes; cluster 2: n = 471 genes; cluster 3: 
n = 442 genes; cluster 4: n = 392 genes; Fisher’s exact test followed by 
Benjamini–Hochberg correction for multiple comparisons). e, Principal 
component analysis of RNA-seq results in c (n = 3 cultures). The top 
5% differentially expressed genes were considered for this analysis. For 
each of the two main principal components (PC1 and PC2), the fraction 
of inter-sample variance that they explain and their proposed biological 
meaning are reported. f, Proportion of transcripts marked by at least 
one high-confidence m6A peak23 in transcripts significantly up- or 
downregulated following WTAP iKD in hESCs maintained in the presence 
of activin (left), or following inhibition of activin–NODAL signalling for 
2 h with SB431542 in control cells (right). Differential gene expression was 
calculated in three cultures using the negative binomial test implemented 
in DEseq2 with a cutoff of P < 0.05 and abs.FC > 2. The number of genes 
in each group and the hypergeometric probabilities of the observed 
overlaps with m6A-marked transcripts are reported (n.s.: not significant at 
95% confidence interval).
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Life Sciences Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life 
science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list 
items might not apply to an individual manuscript, but all fields must be completed for clarity. 
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research 
policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist. 
    Experimental design
1.   Sample size
Describe how sample size was determined. No power calculations were performed. Sample size was determined depending on 
the experiment type based on what is standard practice in the field of pluripotent 
stem cell biology to statically examine a large effect within an in vitro system which 
experiences only limited biological variability (n=2-4, see Figure Legends).
2.   Data exclusions
Describe any data exclusions. No data points were excluded from any of the analyses presented.
3.   Replication
Describe whether the experimental findings were 
reliably reproduced.
All of the presented experiments were successfully reproduced.
4.   Randomization
Describe how samples/organisms/participants were 
allocated into experimental groups.
No randomization was performed since this was not relevant to the study: all 
treatment/control experiments were performed on the same starting cell 
population (no covariates).
5.   Blinding
Describe whether the investigators were blinded to 
group allocation during data collection and/or analysis.
No blinding was performed. This was deemed unnecessary since none of the 
analyses reported involved procedures that could be influenced by investigator 
bias (such as manual counting/measuring and/or morphological assessments). 
Indeed, all analyses presented involved automated processing of data through 
experimental instrumentation and/or computing procedures (including counting of 
PLA signals presented in Fig. 2d, see the Methods)
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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6.   Statistical parameters 
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the 
Methods section if additional space is needed). 
n/a Confirmed
The exact sample size ( ) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same 
sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more 
complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g.  values) given as exact values whenever possible and with confidence intervals noted
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
   Software
Policy information about availability of computer code
7. Software
Describe the software used to analyze the data in this 
study. 
All of the software used for the analyses presented is described in detail in the 
relevant Methods, which also describes the relevant parameters used when these 
were not the default. The software used was: MaxQuant, Perseus, Cytoscape, 
Enrichr, ImageJ, R/Bioconductor, Trimmomatic, TopHat 2.0.13, MetDiff, fCCAC 
v1.0.0, RSeQC-2.6, RCAS, DREME, DESeq2, Cufflinks, GraphPad Prism 6, Sickle, 
Samtools view, SeqMonk, timecourse (Bioconductor). All bioinformatic scripts have 
been deposited to GitHub (http://github.com/pmb59/neMeRIP-seq).
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made 
available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub).  guidance for 
providing algorithms and software for publication provides further information on this topic.
   Materials and reagents
Policy information about availability of materials
8.   Materials availability
Indicate whether there are restrictions on availability of 
unique materials or if these materials are only available 
for distribution by a for-profit company.
All unique materials (cell lines and plasmids) are readily available from the authors
9.   Antibodies
Describe the antibodies used and how they were validated 
for use in the system under study (i.e. assay and species).
All of the antibodies used are detailed in Supplementary Table 5, which also 
reports the application for which they were used and the amount/dilution. The list 
includes: anti-CREBBP (Cell Signalling 7389); anti-EP300 (Santa Cruz sc-584); anti-
FOXH1 (R&D BAF4248); anti-METTL14 (Sigma-Aldrich HPA038002); anti-METTL3 
(Proteintech 15073-1-AP, and Bethyl Lab A301-567A); anti-NANOG (R&D AF1997, 
and Abcam ab21624); anti-OCT4/POU5F1 (Santa Cruz sc-5279); anti-SETDB1 (Cell 
Signalling 2196); anti-SMAD2/3 (R&D AF3797, and Cell Signalling 12470S); anti-
SNON/SKIL (Santa Cruz sc-9595x); anti-SOX1 (R&D AF3369); anti-SOX17 (R&D 
AF1924); anti-TUB4A4 (Sigma-Aldrich T6199); anti-WTAP (Bethyl Lab A301-436A). 
All of the antibodies were validated to recognize the relevant human protein, and 
most of them were specifically validated for the relevant application, as specified 
on the relevant catalog pages on the suppliers' websites. In the few cases in which 
the antibody was not previously validated for a specific application, extensive 
testing in house with the appropriate negative controls was performed to confirm 
the specificity (see Methods and Figure legends). Such applications were: anti-
METTL14 (IP and ChIP); anti-METTL3 (ChIP); anti-NANOG (flow cytometry and PLA); 
anti-SMAD2/3 (RIP and PLA); anti-SOX1 (flow-cytometry); anti-WTAP (PLA, RIP, and 
ChIP).
3




10. Eukaryotic cell lines
a.  State the source of each eukaryotic cell line used. The H9 hESC line was obtained from WiCell (Madison, Wisconsin). The A1ATR/R 
hiPSC line was obtained in house and previously described in Yusa et al 2011. 
 
Yusa, K. et al. Targeted gene correction of alpha1-antitrypsin deficiency in induced 
pluripotent stem cells. Nature 478, 391-4 (2011).
b.  Describe the method of cell line authentication used. No authentication was performed on the H9 hESCs as they were used directly from 
the commercial supplier. The A1ATR/R was genotyped in house to confirm the 
presence of A1AT R/R allele. Both cell lines were routinely karyotyped by standard 
G-banding to confirm euploidy.
c.  Report whether the cell lines were tested for 
mycoplasma contamination.
Yes, mycoplasma screening was performed every month.
d.  If any of the cell lines used are listed in the database 
of commonly misidentified cell lines maintained by 
ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
    Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
11. Description of research animals
Provide details on animals and/or animal-derived 
materials used in the study.
No animals were used
Policy information about studies involving human research participants
12. Description of human research participants
Describe the covariate-relevant population 
characteristics of the human research participants.
The study did not involve human research participants.
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Flow Cytometry Reporting Summary
 Form fields will expand as needed. Please do not leave fields blank.
    Data presentation
For all flow cytometry data, confirm that:
1.  The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
2.  The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of 
identical markers).
3.  All plots are contour plots with outliers or pseudocolor plots.
4.  A numerical value for number of cells or percentage (with statistics) is provided.
    Methodological details
5.   Describe the sample preparation. Biological samples: H9 hESCs (Extended Data Figure 7f), or hESC-derived 
neuroectoderm (Extended Data Figure 8b). Single cell suspensions were 
prepared by incubation in cell cell dissociation buffer (CDB; Gibco) for 10’ 
at 37° followed by extensive pipetting. Cells were washed twice with PBS 
and fixed for 20’ at 4°C with PBS 4% PFA. After three washes with PBS, 
cells were first permeabilized for 20’ at RT with PBS 0.1% Triton X-100, 
then blocked for 30’ at RT with PBS 10% donkey serum. Primary and 
secondary antibodies incubations (Supplementary Table 5) were 
performed for 1h each at RT in PBS 1% donkey serum 0.1% Triton X-100, 
and cells were washed three times with this same buffer after each 
incubation.
6.   Identify the instrument used for data collection. Cyan ADP flow cytometer (Beckman Coulter)
7.   Describe the software used to collect and analyze 
the flow cytometry data.
Data collection: Summit software (Beckman Coulter). Data analysis: FlowJo 
X
8.   Describe the abundance of the relevant cell 
populations within post-sort fractions.
No cell sorting was performed in the study
9.   Describe the gating strategy used. Cells were first gated on the basis of forward and side scatter properties, 
after which singlets were isolated on the basis of relationship between 
side scatter area peak area and width. A secondary-only negative control 
was used to determine the background fluorescence, and positive cells 
were quantified by setting a boundary so that less than 1% of the 
secondary-only control cells would be considered positive.
 Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
